Acute hepatic necrosis associated with the administration of mebendazole to dogs.
Mebendazole was administered to 7 adult Dachshunds and 2 adult Doberman Pinschers at 6-month intervals for routine parasite control. Two weeks after the 1st treatment, a 3-year-old Dachshund died of acute hepatic failure. Approximately 2 weeks following the 2nd treatment, two 5-year-old Dachshunds and one 3-year-old Dachshund had evidence of acute hepatic necrosis; 1 of these dogs died of fulminant hepatic failure. Typical clinical signs in affected dogs included anorexia, depression, vomiting, icterus, and hemorrhagic diarrhea. Two additional Dachshunds had biochemical evidence of hepatic dysfunction, ie. high serum alanine aminotransferase and serum alkaline phosphatase activities. One Dachshund and 2 Doberman Pinschers had no clinical or laboratory evidence of hepatic disease.
D000208:Acute Disease; D000818:Animals; D001562:Benzimidazoles / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000473:pathology / Q000662:veterinary; D004283:Dog Diseases / Q000139:chemically induced* / Q000473:pathology; D004285:Dogs; D005260:Female; D008107:Liver Diseases / Q000473:pathology / Q000662:veterinary*; D008463:Mebendazole / Q000009:adverse effects*; D009336:Necrosis
D001562:Benzimidazoles; D008463:Mebendazole